AIML Announces SEDAR Filing

Rhea-AI Summary

AI/ML Innovations (OTCQB:AIMLF) has filed an amended and restated management's discussion and analysis (MD&A) for the periods ending January 31, 2025, following a review by the British Columbia Securities Commission. The amended filing addresses several disclosure deficiencies.

The enhanced disclosure includes details about new strategic initiatives, R&D activities, operational results, and the acquisition of Quantum Sciences Ltd. Additional information covers related party payments, an exit agreement with Tech2Heal, and other minor updates. The complete Amended MD&A is accessible on SEDAR+.

Positive

• Proactive compliance with regulatory requirements through enhanced disclosure
• Strategic acquisition of Quantum Sciences Ltd and associated intellectual property

Negative

• Required amendments to MD&A due to disclosure deficiencies identified by regulators
• Exit agreement with Tech2Heal indicating discontinued business relationship

VANCOUVER, BC / ACCESS Newswire / August 21, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is issuing the following press release to clarify its disclosure as a result of a review by the British Columbia Securities Commission.

The Company announces today that it has filed an amended and restated management's discussion and analysis for the three and nine month periods ended January 31, 2025 (the "Amended MD&A") in order to rectify certain disclosure deficiencies, including:

• to provide enhanced disclosure relating to (i) new strategic initiatives and R&D activities of the Company; (ii) the results of operations of the Company for the three and nine month periods ended January 31, 2025; and (iii) the acquisitions by the Company of Quantum Sciences Ltd. and certain other intangible assets and associated intellectual property during the period;

• to incorporate additional details regarding payments made to related parties during the period;

• to include a discussion of the exit agreement with Tech2Heal; and

• to incorporate other minor housekeeping changes.

The Amended MD&A is available on SEDAR+ at www.sedarplus.ca.

For more information about AIML:

For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.

Contact:

Blake Fallis
(778) 405-0882
info@aiml.health

About AIML Innovations Inc.
https://aiml.health/

AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care.

AIML's shares trade on the Canadian Securities Exchange (CSE: AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).

On behalf of the Board of Directors:
Paul Duffy, Chairman

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. Such statements remain subject to various risks, including risks relating to the proposed future operations of the Company, availability of funding, industry developments and competition. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company disclaims any obligation to update such forward looking statements other than as required by law.

SOURCE: AI/ML Innovations, Inc.

View the original press release on ACCESS Newswire

FAQ

What changes did AIML (AIMLF) make to its MD&A filing in August 2025?

AIML enhanced its MD&A disclosure to include details about strategic initiatives, R&D activities, operational results, the Quantum Sciences acquisition, related party payments, and the Tech2Heal exit agreement.

Why did AIML (AIMLF) need to amend its January 2025 MD&A?

The amendment was required following a review by the British Columbia Securities Commission to address disclosure deficiencies in the original filing.

What acquisitions did AIML (AIMLF) disclose in its amended MD&A?

AIML disclosed the acquisition of Quantum Sciences Ltd, along with certain intangible assets and associated intellectual property.

What is the significance of AIML's exit agreement with Tech2Heal?

The exit agreement with Tech2Heal represents a discontinued business relationship, which required disclosure in the amended MD&A for transparency to investors.